KLK3 and prostate cancer: In the latest clinical study, which included 60 patients diagnosed with prostate cancer exhibiting low PSA levels, 18F-PSMA-1007 PET/MRI detected 53 lesions in 45 patients, resulting in a detection rate of 75%.